galantamine has been researched along with clorgyline in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aktumsek, A; Alcaro, S; Bagetta, D; Carradori, S; De Monte, C; De Vita, D; Guglielmi, P; Ortuso, F; Petzer, A; Petzer, JP; Secci, D; Zengin, G | 1 |
| Brandão, P; Burke, AJ; Fernández-Bolaños, JG; Leitzbach, L; López, Ó; Pineiro, M; Stark, H | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
| Alcaro, S; Bagetta, D; Burke, AJ; Carreiro, EP; Fernández-Bolaños, JG; Hagenow, S; Leitzbach, L; López, Ó; Marques, C; Moutayakine, A; Stark, H | 1 |
1 review(s) available for galantamine and clorgyline
| Article | Year |
|---|---|
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
3 other study(ies) available for galantamine and clorgyline
| Article | Year |
|---|---|
Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.
Topics: Acetylcholinesterase; Animals; Antioxidants; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Horses; Humans; Hydrazones; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Structure-Activity Relationship | 2018 |
Ugi Reaction Synthesis of Oxindole-Lactam Hybrids as Selective Butyrylcholinesterase Inhibitors.
Topics: | 2021 |
Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Horses; Kinetics; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2022 |